Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Alliance Grants

Université de Montréal

$50,000.00

Quantitative Approaches to Understand Differential Immune Responses in COVID-19

EF 2020-21

Résumé
The novel coronavirus SARS-CoV-2 that emerged in late 2019 is the source of a global pandemic and ongoing public health crisis. Mounting evidence points to dysregulated and hyper-reactive inflammatory responses, including hyperinflammation and cytokine storms, as particular presentations in severe COVID-19. Further, since the start of the pandemic, the SARS-CoV-2 virus causing COVID-19 has evolved from its original RNA sequence that came from human transmission of an animal viral strain. Overall, the mechanisms of the immune response after infection (by the original or a mutated strain) remain to be delineated. Here we will develop quantitative tools with which we can interrogate SARS-CoV-2 infection and COVID-19 clinical manifestation to distinguish clinically-actionable diagnostic markers. This will be accomplished through a broad, international collaboration between academic, industrial, and health care partners who will work together to develop mathematical and computational platforms whose results will be immediately translated into pre-clinical and clinical settings, aiding to refine experimental questions and improve patient care. Ultimately, by improving our understanding of SARS-CoV-2 infection and immune responses to novel coronavirus, our results will rationalize the search for candidate therapies and the pre-clinical decision making process, and contribute to reducing clinical trial failures and bettering patient outcomes.
Programme
Alliance Grants
Emplacement
Quebec, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
NSERC's Awards Data

Tel que publié

Application id
554923-2020
Name nom
Craig, Morgan
Department département
Mathématiques et de statistique
Organization id
63
Institution établissement
Université de Montréal
Province en
Québec
Province fr
Québec
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2020
Competition year année de concours
2020
Award amount
50000
Program id
ALLRP
Program name en
Alliance Grants
Program name fr
Subventions Alliance
Group en
Research partnerships programs
Group fr
Programmes de partenariat
Committee code
96
Committee name en
RPP Internal Decision Cttee
Committee name fr
Cté de décision interne - PPR
Area of application code
1211
Area of application group en
Advancement of knowledge
Area of application group fr
Avancement des connaissances
Area of application en
Medical and health sciences
Area of application fr
Sciences médicales et de la santé
Research subject code
2957
Research subject group en
Applied mathematics
Research subject group fr
Mathématiques appliquées
Research subject en
Mathematical biology andphysiology
Research subject fr
Mathématiques de la biologie et de la physiologie
Installment
inst:1 - 1
Partie
1
Nb partie
1
Application title
Quantitative Approaches to Understand Differential Immune Responses in COVID-19
Keyword
NSERC
Application summary
The novel coronavirus SARS-CoV-2 that emerged in late 2019 is the source of a global pandemic and ongoing public health crisis. Mounting evidence points to dysregulated and hyper-reactive inflammatory responses, including hyperinflammation and cytokine storms, as particular presentations in severe COVID-19. Further, since the start of the pandemic, the SARS-CoV-2 virus causing COVID-19 has evolved from its original RNA sequence that came from human transmission of an animal viral strain. Overall, the mechanisms of the immune response after infection (by the original or a mutated strain) remain to be delineated. Here we will develop quantitative tools with which we can interrogate SARS-CoV-2 infection and COVID-19 clinical manifestation to distinguish clinically-actionable diagnostic markers. This will be accomplished through a broad, international collaboration between academic, industrial, and health care partners who will work together to develop mathematical and computational platforms whose results will be immediately translated into pre-clinical and clinical settings, aiding to refine experimental questions and improve patient care. Ultimately, by improving our understanding of SARS-CoV-2 infection and immune responses to novel coronavirus, our results will rationalize the search for candidate therapies and the pre-clinical decision making process, and contribute to reducing clinical trial failures and bettering patient outcomes.